covid-19 research

GlycoSeLect Endorses Manifesto for EU COVID-19 Research

October 2020 – GlycoSeLect has joined the list of institutions that support the European Commission manifesto for COVID-19 research, to ensure that coronavirus research results are accessible to all.

GlycoSeLect is a proud member of the synBIOcarb Innovative Training Network, which received grant funding under the Marie Skłodowska Curie European Union’s Horizon 2020 research and innovation programme. As part of this network, GlycoSeLect CEO, Robert Dunne, consented to Jean-Eric Paquet, the EU Director-General Research & Innovation, request to agree and endorse the principles proposed for maximising the accessibility of research results in the fight against COVID-19.

“COVID-19 is a huge medical challenge facing the world. Everyone working in the pharmaceutical industry has patient focus as their motivation, right now everyone could be that patient. Therefore, it is right and proper that research results are made available to all”, expressed Mr Dunne.

Following the CEO initiative, GlycoSeLect has become a signatory of the manifesto, joining a list of more than 500 institutions and 1500 individuals in Europe and beyond.

Read and sign the manifesto here.

About GlycoSelect Ltd

GlycoSeLect Ltd develops innovative technologies for the analysis, characterisation and purification of biopharmaceuticals. These next-generation products are highly specific for glycan structures improving product development and improving the cost-efficiency of their manufacturing. GlycoSeLect specialises in the development of proteins based on recombinant prokaryotic lectins RPLs. Our RPL products advance efficient detection, analysis and selective isolation of glycosylated pharmaceutical products. GlycoSeLect’s family of RPLs products are associated with market-leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness in process development.

More Stories